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Qi-Fa Liu,1 Zhi-Ping Fan,1 Yu Zhang,1 Zu-Jun Jiang,2 Chun-Yan Wang,3 Dan Xu,1
Jing Sun,1 Yang Xiao,2 Huo Tan3For patients with advanced leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-
HSCT), a major obstacle to success, especially in those with a high leukemia cell burden, is relapse of the under-
lying disease. To improve the outcome of allo-HSCT for refractory leukemia, we investigated the strategy of
sequential intensified conditioning and early rapid tapering of prophylactic immunosupressants therapy for
graft-versus-host disease (GVHD) during the early stage after transplantation. A total of 51 patientswith refrac-
tory leukemia (median age, 30.0 years; unfavorable karyotypes, 49%) receivedfludarabine (Flu) 30mg/m2/day and
cytarabine 2 g/m2/day (on days210 to26), 4.5 Gy total body irradiation (TBI)/day (on days25 and24), and
cyclophosphamide (Cy) 60 mg/kg/day and etoposide 600 mg/day (on days23 and22) for conditioning. Cyclo-
sporine A (CsA) was withdrawn rapidly in a stepwise fashion to avoid overwhelming GVHD reactions if acute
GVHD(aGVHD)didnot developat day130.All 51patientsdeveloped regimen-related toxicities (13with grade
III-IV); 93.9% of them achieved complete remission by day130. Median follow-up was 41months (range, 6.6 to
92.2months); 5-yearoverall survival (OS) anddisease-free survival (DFS)were 44.6%6 8.1% and38.2%6 7.7%,
respectively. Thirteen patients relapsed; the 3-year cumulative incidence of leukemia relapse was 33.3%. On
multivariate analysis, cytogenetic status was the only significant pretransplantation factor. Survival was
better in patients with grade I or II aGVHD than in thosewithout aGVHD. Our data indicate that the sequential
strategy of cytoreductive chemotherapy followed immediately by intensified myeloablative (MA) conditioning
for allo-HSCTand rapid tapering of prophylactic immunosuppressants for GVHD in the early stage after trans-
plantation has an acceptable toxicity profile and may be a better approach to treating refractory leukemia.
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The management of refractory leukemia in adults
is very difficult. Although several salvage regimens
have been used successfully to induce remission in
this group of patients, the duration of remission is of-
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(allo-HSCT) is commonly perceived as the only cura-
tive option for refractory leukemia [4-7]. Unfortu-
nately, however, the outcome of allo-HSCT in
patients with refractory leukemia depends largely on
disease status at the time of transplantation [6-8]. Pa-
tients with an advanced disease who proceed directly
to HSCT, especially those with a high leukemia cell
burden, are likely to do poorly [4,7,9]. The relapse
rate exceeds 50% in these patients after transplantation
with a standardmyeloablative (MA) regimen consisting
of total body irradiation (TBI) or busulfan (Bu) com-
bined with cyclophosphamide (Cy) [10-12]. Modifica-
tions of the MA conditioning regimen using various
combinations of chemotherapy and radiotherapy have
failed to reduce the risk of relapse in refractory patients
[13,14]. Reduced-intensity conditioning (RIC) regi-
mens have been advocated to reduce transplantation-
associated toxicity in elderly or medically unfit patients
[15,16]; however, in advanced leukemia, RIC may not
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leukemia (GVL) effect to occur, and disappointing re-
sults have been reported with RIC transplantation in
patients with advanced disease [17]. The intensity of
the conditioning regimen has been shown to directly
affect the relapse rate and disease-free survival (DFS)
after allo-HSCT for refractory leukemia [18,19].
Approaches to improving outcomes in patients with
refractory leukemia include administering salvage che-
motherapy to decrease the leukemia cell burden before
transplantation and increasing the intensityof the condi-
tioning regimen. Suitable salvage regimens and intensi-
fied conditioning regimens must have acceptable
toxicity and mortality, however. Recently, Schmid and
coworkers [7,20] reported that a sequential regimen of
salvage chemotherapy and RIC was effective and had
an acceptable toxicity profile in allo-HSCT to treat
acute myelogenous leukemia (AML) and myelodysplas-
tic syndrome (MDS). But, despite these encouraging
overall results, the relapse rate remains significant [7,20].
In addition to the antileukemic effect of condition-
ing regimens, the therapeutic efficacy of allo-HSCT
also relies on the GVL reaction. Prophylactic transfu-
sion of donor lymphocytes is commonly used to
further exploit the GVL reaction in patients with re-
fractory leukemia [21,22]. Clinical observations show
that cyclosporine A (CsA) withdrawal can induce com-
plete remission (CR), and this is generally used as first-
line treatment in patients with relapsed leukemia after
allo-HSCT [23-25]. Recently, our group introduced
a regimen of sequentially intensified conditioning
and tapering of prophylactic immunosuppressants for
graft-versus-host disease (GVHD) in allo-HSCT for
patients with refractory leukemia. The regimen con-
sists of cytoreductive chemotherapy, followed imme-
diately by intensified MA conditioning and then
rapid tapering of prophylactic immunosuppressants
for GVHD in the early stage after transplantation. A
preliminary subgroup analysis of this trial suggested
that patients with refractory leukemia might especially
benefit from this strategy [26]. The differences be-
tween our trial and the trial reported by Schmid and
coworkers are in the heterogeneity of the patients
included, the drugs used for and intensity of condition-
ing, the interval between cytoreductive chemotherapy
to conditioning, and the prophylactic immun-
osuppressive therapy for GVHD. The current study
was initiated to assess the feasibility and efficacy of
this approach in patients with refractory leukemia in
a multicenter trial involving 3 institutions in China.PATIENTS AND METHODS
Patients and Eligibility Criteria
The study cohort comprised 51 patients with adult
refractory leukemia divided into 2 groups. The firstgroup included 18 consecutive patients with refractory
leukemia treated at Nanfang Hospital between May
2001 andMay 2004; their records were reviewed retro-
spectively. The second group included 33 consecutive
patients with refractory leukemia who were involved in
a prospective multicenter trial at Nanfang Hospital,
Southern Medical University, Guangzhou General
Hospital of Guangzhou Command, and First Affili-
ated Hospital, Guangzhou Medical College between
June 2004 and June 2008. The patients’ median age
at transplantation was 30 years (range, 14 to 53 years).
They were categorized as having AML, acute lympho-
blastic leukemia (ALL), acute biphenotypic leukemia
(ABL), or chronic myelogenous leukemia with blast
crisis (CML-BC) according to the World Health Or-
ganization classification system [27]. All patients who
met at least 1 of the following criteria for refractory
leukemia were included: (1) primary induction failure
(PIF) after 2 or more cycles of chemotherapy, (2) re-
lapse refractory to salvage combination chemotherapy,
and (3) CML-BC resistant to tyrosine kinase inhibitors
and PIF after 2 or more cycles of chemotherapy. The
final inclusion criterion was age between 14 and 55
years. Exclusion criteria included creatinine clearance
\ 50 mL/min, bilirubin or transaminase level . 2
times the upper limit of normal, cardiac shortening
fraction\ 30%, and pregnancy. The study was per-
formed in accordance with the modified Helsinki Dec-
laration, and the protocol was approved by the
respective ethical review boards before study initia-
tion. All patients provided written informed consent.
HLATyping
Standard serologic typing was used forHLA-A and
-B, and genomic high-resolution molecular typing was
used for HLA-DRB1 inHLA-matched sibling donors.
Genomic high-resolution molecular typing was used
for HLA-A, -B, and -DRB1 for HLA-mismatched
family donors and unrelated donors.
Sequential Intensified Conditioning Regimen
The sequential intensified conditioning regimen
for allo-HSCT has been described in detail previously
[26]. In brief, patients received fludarabine (Flu) 30
mg/m2 and moderate- dose cytarabine (Ara-C), 2 g/m2,
from day 210 to day 26, 4.5 Gy of TBI on days 25
and 24, and Cy 60 mg/kg and etoposide 600 mg/day
on days 23 and 22.
GVHD Prophylaxis and Treatment
In our preliminary single-center study from May
2001 to May 2004, CsA only was administered for
GVHD prophylaxis in all 10 patients undergoing
HLA-matched sibling donor transplantation. In our
multiple-center study, CsA with methotrexate (MTX)
(on days 11 and 13) was administered for GVHD
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matched sibling donor transplantation. Patients receiv-
ing an unrelated donor, parent donor, or more than 1
locus HLA-mismatched sibling donor transplant
received CsA 1 MTX (on days 11, 13, and 16) and
human antithymocyte globulin (ATG [Thymoglobu-
lin; Genzyme, Cambridge, MA]; 2.5 mg/kg/day on
days 23, 22, and 21) as GVHD prophylaxis. CsA 1
MTX (on days 11, 13, and 16), and mycophenolate
mofetil (MMF; 0.5 g twice a day on days 0 to 128)
was used in patients receiving a 1 locus HLA-
mismatched sibling donor transplant as GVHD pro-
phylaxis. Methylprednisolone 2 mg/kg/day was given
to treat acute GVHD (aGVHD). ATG or ATG
combined with CD25 monoclonal antibody (mAb) and
another immunosuppressant agent was initially given
to patientswith glucocorticosteroid-resistant aGVHD.
Corticosteroids and CsA were used initially to treat
chronic GVHD (cGVHD), and the combination with
various immunosuppressant agents was used to treat
cGVHD that was unresponsive to initial therapy.
CsAWithdrawal
CsA was withdrawn rapidly in a stepwise fashion
(ie, total dose reduced by 20%/week) to avoid an over-
whelming GVHD reaction in patients who did not
develop aGVHD by day 130 posttransplantation.
For those who developed aGVHD, methylpredniso-
lone was added to the regimen.
Infection Prophylaxis
Oral sulfamethoxazole and norfloxacin were given
to all patients. Acyclovir was given daily from the
beginning of conditioning therapy to engraftment,
and then daily for 7 days every 2 weeks for up to 1
year after transplantation. Ganciclovir was given for
2 weeks before transplantation for prophylaxis of cyto-
megalovirus (CMV) infection, and then again during
periods of CMV viremia within 1 year after transplan-
tation. Antifungal agents were administered 5 days
before transplantation. Fluconazole (0.3 g$day21 for
up to 160 days after transplantation) was used in pa-
tients with no history of invasive fungal infection
(IFI); those with a history of IFI received i.v. itracona-
zole (0.4 g$day21), voriconazole (0.4 g$day21), or Am-
Bisome (2 mg$kg21 day21). Oral itraconazole and
voriconazole were started when the peripheral white
blood cell (WBC) count exceeded 2.0  109/L and
was discontinued after 90 days posttransplantation.
Evaluation Points and Definitions
Our data were analyzed on December 31, 2008.
Evaluation points included hematopoietic engraft-
ment, regimen-related toxicities (RRTs), infections,
disease response, relapse, mortality, and overall sur-
vival (OS) and DFS from transplantation, as well asthe incidence and severity of aGVHD and cGVHD.
Hematopoietic engraftment was defined as the first
of 2 consecutive days with an absolute neutrophil
count (ANC) in the peripheral blood (PB) exceeding
0.5  109/L and the first of 3 days with an absolute
platelet count exceeding 20  109/L without transfu-
sion support. RRTs were graded according to Bear-
man’s criteria [28]; aGVHD and cGVHD were
graded as described previously [29]. Cytogenetic sub-
groups were classified according to criteria described
previously [30]; CML-BC accompanied by complex
aberrations was considered unfavorable, and the other
subgroups were considered intermediate. On days 0,
115 (neutrophil engraftment), and 130, disease
response was assessed by bone marrow (BM) aspira-
tion. Complete remission (CR) was defined as\ 5%
blasts with no evidence of dysplasia in the BM and
no manifestations of leukemia outside the hematopoi-
etic system. Partial remission (PR) was defined as
\ 30% blasts with or without extramedullary leuke-
mia. No response was defined as a failure to meet the
criteria for CR or PR. Donor chimerism in the PB
and BM was analyzed on days 115, 130, 190, and
1180 using fluorescein in situ hybridization (FISH)
in sex-mismatched transplantation and short tandem
repeat analysis in sex-matched transplantation. Com-
plete chimerism (CC) was defined as . 95% donor
cells detected; mixed chimerism (MC), as 5% to 95%
donor cells detected. Molecular and cryptogenic re-
lapse was assessed based on chimerism status and pres-
ence of the tumor target gene marker; relapse was
defined as a . 5% decrease in donor chimerism status
or the reappearance of the tumor target gene marker.
Hematologic relapse was defined by the reappearance
of blasts in the PB, by any manifestation of leukemia
outside the hematopoietic system, or by . 5% blasts
in the BM smear.
Follow-Up
All patients were followed up weekly for the first 6
months, monthly between 6 to 24 months, every 3
months between 25 to 36 months, and every 6 months
beyond 36 months after transplantation.
Statistical Analysis
Numerical variables were analyzed as categories
based on their values being below or above the median
of the entire cohort, as indicated in the Results section.
For comparison of group characteristics (eg, RRTs),
the c2 test, Fisher’s exact test, and Student’s t-test
were used for univariate analysis. aGVHD and
cGVHD were analyzed as time-dependent variables.
The relationships between GVHD and infection,
relapse, and OS were analyzed using the Spearman
rank test. OS and DFS were estimated using the
Kaplan-Meier method. The log-rank test and a Cox
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analysis of risk factors for time-to-event variables.
Probabilities of nonrelapse mortality (NRM) and re-
lapse mortality were calculated using reciprocal cumu-
lative incidence estimates to account for competing
risks. The SPSS software package (SPSS, Chicago,
IL) was used for all data analysis.RESULTS
Patient, Donor, and Transplant Characteristics
Patients’ characteristics are summarized inTable 1.
Within the study population, 3 patients had comorbid-
ities; 2 had hypertension, and 1 had hypertension and
diabetes mellitus. Two patients had a history of pul-
monary tuberculosis, and 11 had a history of IFI before
transplantation. Active Aspergillus pneumonia was
diagnosed in 3 patients at the time of transplantation.
Before conditioning, the median percentage of leuke-
mic blasts in the BM was 26% (range, 8% to 92%;
mean, 33.6% 6 23.0%). Six patients had extramedul-
lary disease before conditioning, including 2 with cen-
tral nervous system leukemia (CNSL), 1 with soft
tissue infiltration, and 3 with lymph node infiltration.Table 1. Patient Characteristics before Transplantation
Male/female 36 (70.6%)/15 (29.4%)
Median age, years (range) 30 (14-53)
Diagnosis
AML 20 (39.2%)
ALL 16 (31.4%)
ABL 9 (17.6%)
CML-BC-AML 6 (11.8%)
Cytogenetic subgroup
Favorable 4 (7.8%)
Intermediate 18 (35.3%)
Unfavorable 20 (39.2%)
Unknown 9 (17.6%)
Stage of treatment before transplantation
Primary induction failure 29 (58.9%)
Refractory relapse after CR1 < 6 months 9 (17.6%)
Refractory relapse after CR1 > 6 months 7 (13.7%)
Refractory relapse after CR2 3 (5.9%)
Previous autologous transplantation 3 (5.9%)
Median marrow blasts before conditioning
(range)
26% (8.0-92.0%)
Extramedullary disease at time of
transplantation
6 (11.6%)
CNSL 2
Soft tissue and lymph node involvement 4
Number of chemotherapy cycles before
transplantation
Two 2 (3.9%)
Three 11 (21.6%)
Four 9 (17.6%)
Five or six 12 (23.5%)
More than six 17 (33.3%)
Median (range) 5 (2-13)
Median time from diagnosis to transplantation,
days (range)*
215 (85-1253)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; ABL, acute biphenotypic leukemia; CML-BC, chronic myelo-
genous leukemia with blast crisis; CNSL, central nervous system leuke-
mia.
*Median time in CML-BC was defined as blast crisis to transplantation.The cytogenetic subgroups according to the criteria
[30] were favorable in 4 cases, intermediate in 18 cases,
and unfavorable in 20 cases. The karyotype was
unknown in 9 cases. All but 1 patient (who died of
bacterial septicemia during the conditioning) received
a stem cell transfusion. Donor and transplant charac-
teristics are summarized in Table 2.Hematopoietic Engraftment and Chimerism
All patients achieved hematopoietic engraftment,
except for 1 patient who died of bacterial septicemia
during conditioning and 1 patient who died of an
RRT on day 13 after transplantation. The median
time to neutrophil engraftment was 12 days (range, 8
to 19 days), and the median time to platelet engraft-
ment was 15 days (range, 10 to 28 days). Donor chime-
rism was analyzed in the BM at the time of neutrophil
engraftment and on day130 after transplantation. All
49 evaluable patients achieved donor chimerism,
including 17 (33.3%) with CC and 32 (62.7%) with
MC (with donor chimerism ranging from 58% to
93%) at the time of neutrophil engraftment, and 48
of these 49 patients (98.0%) had CC and 1 had MC
by day 130 after transplantation.RRTand Infection within 100 Days
Posttransplantation
The conditioning was tolerated by all patients
except 1 patient who died of an RRT (ie, heart toxic-
ity). The incidence of RRT was 100% according to
Bearman’s criteria [28]. Toxicity was most common
in the gastrointestinal tract (39/51). Overall, 33
patients developed grade I toxicity and 13 (25.5%)
had grade III-IV toxicity in 1 or more organs (1 organ,
n 519; 2 organs, n 522; 3 or more organs, n 5 10).
Significant central nervous system (CNS) toxicity
was not observed. Three patients developed seizures
related to high CsA levels within 1 month after trans-
plantation. Organ toxicity is summarized in Table 3.Table 2. Donor and Transplant Characteristics
Donor type (n 5 50)
HLA-matched sibling donor 22 (44.0%)
HLA-mismatched sibling donor 4 (8.0%)
One allele mismatched 2 (4.0%)
Two alleles mismatched 2 (4.0%)
HLA-mismatched family donor 5 (10.0%)
One allele mismatched 2 (4.0%)
Two alleles mismatched 3 (6.0%)
HLA-matched unrelated donor 12 (24.0%)
HLA-mismatched unrelated donor 7 (14.0%)
One allele mismatched 3 (6.0%)
Two alleles mismatched 4 (8.0%)
Stem cell source (n 5 50)
Mobilized PBSCs 35 (70.0%)
BM 9 (18.0%)
Mobilized PBSCs + mobilized BM 6 (12.0%)
Median CD34+ cells per graft,  106/kg (range) 8.7 (4.0-21.4)
PBSCs indicates peripheral blood stem cells; BM, bone marrow.
Table 3. Organ Toxicity According to Bearman’s Criteria
Grade 0, n (%) Grade I or II, n (%) Grade III or IV, n (%)
Single Multiple Total Single Multiple Total Single Multiple Total
Heart 11 (61.1) 21 (63.6) 32 (62.7) 6 (33.3) 9 (27.3) 15 (29.4) 1 (5.5) 3 (9.1) 4 (7.8)
Bladder 15 (83.3) 25 (75.8) 40 (78.4) 2 (11.1) 4 (12.1) 6 (11.8) 1 (5.5) 4 (12.1) 5 (9.8)
Kidneys 16 (88.9) 29 (87.9) 45 (88.2) 2 (11.1) 3 (9.1) 5 (9.8) 0 (0.0) 1 (3.0) 1 (2.0)
Lungs 18 (100) 32 (97.0) 50 (98.0) 0 (0.0) 1 (3.0) 1 (2.0) 0 (0.0) 0 (0.0) 0 (0.0)
Liver 14 (77.8) 27 (81.8) 41 (80.4) 3 (16.6) 5 (15.2) 8 (15.7) 1 (5.6) 2 (6.7) 3 (5.9)
CNS 17 (94.4) 31 (90.9) 37 (93.9) 1 (5.6) 2 (6.1) 3 (5.9) 0 (0.0) 0 (0.0) 0 (0.0)
Mucosa 10 (55.6) 19 (60.6) 29 (56.7) 6 (33.3) 14 (42.4) 20 (39.2) 2 (11.1) 5 (15.2) 7 (13.7)
Gut 3 (16.7) 9 (27.3) 12 (23.5) 13 (72.2) 21 (63.6) 34 (66.7) 2 (11.1) 3 (9.1) 5 (9.8)
CNS indicates central nervous system.
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nificantly between the 18 patients in our single-center
retrospective group and the 33 patients in our multi-
center group (Table 3).
Within the first 100 days posttransplantation, 26
patients developed 37 episodes of infection. Fifteen
patients had bacterial infections, including 1 patient
with tuberculosis who had a history of pulmonary
tuberculosis; 4 patients had IFI; 6 patients had viral
infections; 8 patients had mixed infections (6 bacterial
and fungal; 2 bacterial and viral); and 4 patients had
infections of unknown etiology. In addition, 19
patients had CMV viremia, not considered an infec-
tion. Infection was not related to aGVHD (gs 5
0.737; P 5 .072). The site of infection was identified
in 35 of the 37 episodes of infection, including 4 bac-
teremia, 2 septicemia1 lung, 3 septicemia1 perianal,
2 septicemia1 intestinal, 12 lung, 4 mouth1 esopha-
gus, 5 stomach1 intestine, 2 soft tissue, and 1 bladder.
Bacteremia was detected in 11 patients; 9 patients had
symptoms of sepsis or septic shock, and 1 patient
developed CMV pneumonia. In the 3 patients with ac-
tive fungal infection before transplantation, infection
progressed in 1 patient, and infection was controlled
after transplantation in 2 patients. Four patients died
of infection within 100 days posttransplantation.Disease Response
To identify patients who might not benefit from
our sequential intensified conditioning approach, we
examined the BM on day 0 in all 50 evaluable patients.
The median percentage of blasts in the BM was 7.5%
(range, 0% to 38%; mean, 9.1% 6 7.8%). The per-
centage of blasts in the BM was significantly lower
on day 0 than at the start of conditioning (34.5% 6
23.6%; P\ .001). At the time of neutrophil engraft-
ment, 43 patients (87.8%) had \ 5% blasts in the
BM, and all 49 evaluable patients had achieved donor
chimerism. On day130, 46 patients (93.9%) achieved
CR, 2 patients achieved PR, and 1 patient achieved
NR. Two patients with PR had ALL and AML,
accompanied by submaxillary lymph node enlarge-
ment and mediastinal enlargement, respectively, be-fore transplantation. Both of them had\ 5% blasts
in the BM, but, because they had extramedullary leuke-
mia, they achieved only PR. Both developed aGVHD
and achieved CR after withdrawal of CsA. Although
the patient with NR achieved donor chimerism after
transplantation, the rate of donor chimerism was
48% at the time of neutrophil engraftment and 32%
by day 130. This patient did not achieve remission
of leukemia after withdrawal of CsA and chemother-
apy and died of leukemia progression.
GVHD
Grade I-IV aGVHDoccurred in 23 of 49 evaluable
patients (46%) by day130 (grade I, n57; grade II, n5
8; grade III, n5 4; grade IV, n5 4). Themedian day of
onset was day 121 (range, day 17 to day 128). Skin,
liver, and gut involvement was seen in 21, 15, and 14
patients, respectively. Of the 26 patients who did not
develop GVHD by day 130, 15 developed aGVHD
(grade I, n 5 4; grade II, n 5 8; grade III, n 5 3) after
gradual reduction or withdrawal of immunosuppres-
sant agents. In the 7 patients with leukemia recurrence,
aGVHD occurred in 4 of the 6 patients who received
treatment including donor lymphocyte infusion
(DLI) and in 1 patient after withdrawal of CsA.
cGVHD developed in 21 of 42 (50.0%) patients who
survived for more than 100 days, including 2 patients
who developed cGVHD after DLI. The median inter-
val from transplantation to onset of de novo cGVHD
was 141 days (range, 91 to 266 days). Twelve patients
had limited disease, and 9 patients had extensive
disease.
Relapse and Outcome
Thirteen patients (26.5%) relapsed, at a median
time of 4.5 months (range, 3.0 to 8.0 months) after
transplantation, as a result of hematologic disease in
8, a cytogenetic disorder in 2, and extramedullary
disease in 3. The cumulative rate of relapse at 3 years
posttransplantation was 33.3%. Nine patients
(69.2%) relapsed during the first 6 months posttrans-
plantation; these patients had some poor prognostic
characteristics in common, including high-risk
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Ten patients received treatment, and 3 patients aban-
doned treatment. Six patients received treatment in-
cluding DLI, and 4 patients received only
chemotherapy and/or immunosuppressant withdrawal
because of the lack of a suitable donor. Five patients
achieved CR, 1 patient achieved PR, and 4 patients
achieved NR. All patients who achieved CR received
DLI; 1 patient experienced hematologic relapse, 2
patients had a cytogenetic disorder, and 2 patients
sustained extramedullary relapse.
The Spearman rank test demonstrated a negative
correlation between disease relapse and aGVHD
(rs520.418;P5 .004), aswell as a negative correlation
between relapse and cGVHD (rs520.355; P5 .023).
However,OSwas not related to aGVHD (rs520.070;
P5 .631) or cGVHD (rs5 0.120; P5 .457). The Pear-
son c2 analysis indicated that the rate of disease relapse
did not differ significantly among the various types of
disease (c25 2.443; P 5 .486) (Table 4).Figure 1. OS and DFS.OS and DFS
Twenty-six patients were alive at a median follow-
up of 41 months (range, 6.6 to 92.4 months). Causes of
death included leukemia progression (n5 1), infection
(n 5 6), RRT (n 5 1), leukemia relapse (n 5 6),
GVHD (n 5 9), and second tumor (n 5 2, including
lung cancer in 1 patient and posttransplantation lym-
phoproliferative disease in 1 patient). The 100-day
posttransplantation mortality was 21.6% (n 5 11,
including RRT in 1, infection in 3, aGVHD in 5, dis-
ease progression in 1, and posttransplantation lympho-
proliferative disease in 1). Overall, the 12, 32, 52,
and 7-year OS and DFS were 57.7% 6 7.1% and
48.0% 6 7.1%, 49.0% 6 7.6% and 42.4% 6 7.3%,
44.6% 6 8.1% and 38.2% 6 7.7%, and 44.6% 6
8.1% and 38.2% 6 7.7%, respectively (Fig. 1). The
3-year OS and DFS did not differ significantly in our
single-center and multicenter groups (P 5 .642 and
.522, respectively). OS and DFS among all disease
types (AML, ALL, ABL, and CML-BC-AML) also
did not differ significantly according to Kaplan-Meier
analysis (P 5 .803 and .839, respectively).
The development of aGVHD had a significant ef-
fect on outcome. In the posttransplantation period,
when aGVHD developed, OS and DFS were betterTable 4. Diagnosis and Relapse
Diagnosis Relapse, n (%) Nonrelapse, n (%) c2 P
AML 5 (25.0) 15 (75.0) 2.443 .486
ALL 6 (37.5) 10 (62.5)
ABL 1 (11.1) 8 (88.9)
CML-BC-AML 1 (16.7) 5 (83.3)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; ABL, acute biphenotypic leukemia; CML-BC, chronic myelo-
genous leukemia with blast crisis.in patients with grade I or II aGVHD compared with
patients without aGVHD. However, grade III-IV
aGVHD was associated with high mortality and poor
outcome (P 5 .010 for OS and P 5 .006 for DFS;
log-rank, multigroup comparison) (Figure 2). In con-
trast, cGVHD had no significant effect on survival.
Survival Analysis
Risk factors for survival are presented in Table 5.
Four pretransplantation variables were associated
with better OS on univariate analysis: stage at trans-
plantation (others vs PIF), lower circulating blasts at
transplantation (none vs present), BM infiltration by
\ 30% blasts, and favorable cytogenetic status. Four
pretransplantation variables also were associated with
better DFS on univariate analysis: younger age at
transplantation, lower circulating blasts at transplanta-
tion (none vs present), BM infiltration by \ 30%
blasts, and favorable cytogenetic status. Using a Cox
regression model for multivariate analysis, cytogenetic
status (high risk vs other: P 5 .001, hazard ratio [HR]
5 0.224 for OS; P 5 .045, HR 5 0.382 for DFS) was
the only significant pretransplantation factor. In
contrast, age, sex, diagnosis, circulating blasts at trans-
plantation, BM infiltration by blasts at transplantation,
number of chemotherapy cycles before transplanta-
tion, time from diagnosis to transplantation, CD341
cell count in the graft, and HLA typing were not pre-
dictive of outcome.DISCUSSION
For patients with advanced leukemia undergoing
allo-HSCT, a major obstacle to success is relapse of
Figure 2. Influence of acute GVHD on OS (P 5 .010) and DFS (P 5 .006).
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depends largely on the leukemia burden at the time
of transplantation [8]. With standard MA regimens
consisting of TBI or Bu combined with Cy, the relapse
rate (RR) is . 50% for patients who undergo HSCT
with advanced-stage disease [10-12]. Intensified condi-
tioning can reduce the leukemia burden before trans-
plantation and improve the CR rate and long-term
survival in patients with advanced leukemia after
allo-HSCT [7,18-20]. The Flu/Ara-C regimen for sal-
vage chemotherapy in patients with refractory and re-
lapsed leukemia has a reported 40% to 50% overall
probability of achieving CR [1-3,31]. Based on these
results, we used the Flu/Ara-C regimen followed by
a myeloablative regimen, in our patients with refrac-
tory leukemia who underwent allo-HSCT. To identify
those patients who might benefit from our intensified
conditioning regimen, we performed a BM examina-
tion on day 0, and found a markedly lower percentage
of blasts in the BM on day 0 than before the start ofTable 5. Risk Factors for Outcomes
O
Univariate
Sex, male versus female NS
Age, less than versus greater than or equal to
median
NS
Diagnosis, AML versus other NS
Stage at HSCT, PIF versus other .048 (0.387)
Circulating blasts at HSCT, none versus present .007 (7.340)
BM infiltrated by blasts at HSCT, < 30% versus >
30%
.007 (3.271)
Number of chemotherapy cycles before HSCT,
less than versus more than or equal to median
NS
Time from diagnosis to HSCT, less than versus
greater than or equal to median
NS
Cytogenetic status, high risk versus other .001 (0.224)
CD34+ counts in the graft, less than versus
greater than or equal to median
NS
HLA type, matched versus mismatched NS
OS indicates overall survival; DFS, disease free survival; AML, acute myelogeno
induction failure; BM, bone marrow; NS, not significant.conditioning. On day 130 posttransplantation, 48 of
49 patients achieved CR of the BM with no evidence
of dysplasia in the BM. These results confirm the suit-
ability of using Flu/Ara-C with the MA regimen in re-
fractory leukemia to decrease the leukemic burden
before allo-HSCT and increase the CR rate after
allo-HSCT.
RRTs remain a major obstacle when intensified
conditioning regimens are used in allo-HSCT
[32,33]. Flu is widely used for HSCT conditioning in
both MA and nonmyeloablative (NMA) regimens.
Replacing Cy with Flu in MA conditioning can de-
crease the rate of RRTs and treatment-related mortal-
ity (TRM) [34-36]. The combination of Ara-C and
TBI/Cy has been investigated at some transplantation
centers [18,37-41]. Some studies have reported that
adding high-dose Ara-C to MA conditioning can in-
crease pulmonary, neurologic, and cardiac toxicity
[37,38,41]; however, other studies have found that
this addition reduced leukemia relapse with noS DFS
Multivariate (HR) Univariate Multivariate (HR)
NS NS NS
NS .025 (2.541) NS
NS NS NS
NS NS NS
NS .025 (3.767) NS
NS .036 (2.318) NS
NS NS NS
NS NS NS
.017 (0.280) .003 (0.310) .045 (0.382)
NS NS NS
NS NS NS
us leukemia; HSCT, hematopoietic stem cell transplantation; PIF, primary
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reported increased RRTs used 3 g/m2  6 to 12 doses
of Ara-C [37,38,41]. Recently, Schmid and coworkers
[7,20] reported that a sequential regimen of Flu/Ara-
C/amsacrine for salvage chemotherapy and RIC was
effective and had an acceptable toxicity profile in
allo-HSCT for refractory AML and MDS. In our sin-
gle-center phase I study, we observed no significant in-
crease in RRTs in the intensified conditioning regimen
consisting of Flu/Ara-C and TBI/Cy compared with
the standard TBI/Cy conditioning for patients under
the age of 50 years undergoing allo-HSCT for refrac-
tory leukemia [26]. In this multicenter study, for pa-
tients under age 55 years, the incidence of RRTs was
similar to that in the single-center study. Regarding
the association of RRTs with Ara-C, most studies
have demonstrated an association between RRTs and
high-dose Ara-C; the use of moderate doses of Ara-C
in the present study might explain the lower incidence
of RRTs that we found. Infection is a common compli-
cation after allo-HSCT, especially in the early period
after transplantation. Some studies have indicated
that intensified conditioning is complicated by an
increased infection rate [42-44]. We did not perform
a direct, randomized comparison of intensified condi-
tioning with standard TBI-based regimens; however,
the incidence of infections in our cohort appeared to
be similar to that in patients with CR status who un-
derwent allo-HSCT with a standard conditioning reg-
imen in a corresponding time period within 100 days
posttransplantation (data not shown).
In addition to the antileukemic effect of condition-
ing regimens, the therapeutic efficacy of allo-HSCT
also relies on the GVL reaction, which is based on
the interaction of the host’s antigen-presenting cells
and the donor’s immunocompetent cells. Generally,
the occurrence of GVHD is considered to be associ-
ated with the GVL reaction. It is known that leukemia
relapse after allo-HSCT can be successfully treated by
inducing a GVL reaction [7,20,45,46]. DLI, CsA with-
drawal, and cytokines (eg, interferon-alpha and
interleukin-2) are generally used to induce a GVL re-
action in relapsed patients after allo-HSCT. CsA with-
drawal accompanied by GVHD and the GVL reaction
has been observed in some patients undergoing allo-
HSCT and has been used as first-line treatment in pa-
tients with leukemic relapse after allo-HSCT [23-25].
In our cohort of patients, 2 of 3 patients who did not
achieve CR by day 130 achieved CR after the occur-
rence of aGVHDgrade II and III, respectively, and an-
other patient without GVHD did not achieve CR from
a rapid tapering of prophylactic immunosuppressants
for GVHD in the early stages posttransplantation. In
our cohort, Kaplan-Meier analysis also indicated bet-
ter OS and DFS in patients with grade I or II aGVHD
compared with patients without aGVHD. The induc-
tion of GVL through rapid tapering of prophylacticimmunosuppressants during the early stages post-
transplantation is also supported by the low relapse
rate and excellent survival in our entire cohort. Our
strategy of GVHD prophylaxis and CsA withdrawal
resulted in a higher incidence of aGVHD, but the
aGVHD–related lethality was acceptable, and the
incidence of cGVHD was only 45.2% (19/42; 2 pa-
tients developed cGVHD after DLI).
The combination of Flu/Ara-C and the TBI/Cy
conditioning regimen was intended to increase anti-
leukemic efficacy and decrease the leukemia burden
before transplantation. Flu/Ara-C chemotherapy is
aimed mainly at rapidly proliferating malignant cells,
and TBI may have an antileukemic effect on less rap-
idly proliferating or even quiescent leukemic cells.
This approach has proven highly effective, as demon-
strated by the number of leukemic cells in the BM on
day 0 and the rate of CR on day 130 posttransplanta-
tion in our cohort. The success of the GVL reaction in
decreasing the rate of leukemia relapse depends on the
leukemia burden after HSCT. Rapid tapering of pro-
phylactic immunosuppressants for GVHD in the early
stages of the transplantation protocol was intended to
accelerate the GVL reaction in patients with a lower
leukemia burden after allo-HSCT. This concept also
proved highly effective, with 7-year OS and DFS of
44.6% 6 8.1% and 38.2% 6 7.7%, respectively, and
a cumulative relapse rate of 33.3% at 3 years posttrans-
plantation in our cohort. These results compare favor-
ably to those of previous studies on treating refractory
leukemia using standard or intensified conditioning
regimens and allo-HSCT [4,5,14,47,48]. A formal
comparison of our results with those from other inten-
sified conditioning regimens is difficult because of the
heterogeneity of the patient populations, differences in
the intensity of conditioning, and transplantation
approaches. Recently, Schmid and coworkers [7,20]
reported a very promising study that improved OS
and DFS for refractory AML and MDS through
a sequential regimen of Flu/Ara-C/amsacrine chemo-
therapy and RIC for allo-HSCT, along with prophy-
lactic DLI. But, despite these encouraging overall
results, the relapse rate in this study was still signifi-
cant. Our strategy for patients with refractory leuke-
mia undergoing allo-HSCT is similar to that
described by Schmid and coworkers, but our results
are superior to theirs with respect to OS and DFS.
Along with the heterogeneity of the patients included
in our cohort, our protocol differed from theirs in
terms of the intensity of, and drugs used in, condition-
ing, the interval between cytoreductive chemotherapy
and conditioning, the prophylactic immunosuppres-
sive therapy for GVHD, and other aspects. Notably,
Schmid and coworkers used amsacrine in their proto-
col, whereas we did not. In contrast to the results
reported by Schmid and coworkers [7,20], our univar-
iate analysis data indicate that PIF at transplantation
1384 Biol Blood Marrow Transplant 15:1376-1385, 2009Q.-F. Liu et al.was an unfavorable prognostic factor. However, multi-
variate analysis of potential risk factors for outcome
identified favorable cytogenetic status as the only pre-
transplantation variable with a strong association with
better OS andDFS (P5 .001 and .045, respectively). A
reasonable interpretation of our findings is that the pa-
tients with PIF received the same number of
chemotherapy cycles as other patients. Although our
protocol appears to prolong the survival of patients
with refractory leukemia, it cannot overcome the
obstacle of cytogenetic status; patients with high-risk
cytogenetic status have lower OS andDFS. In previous
studies, patients with refractory ALL had a higher
relapse rate and shorter OS than those with refractory
AML after allo-HSCT [7,20,49]; however, to our sur-
prise, in our study, relapse rate and OS were similar in
patients with ALL and those with AML. This finding
might be related to the beneficial profile of our
approach, or possibly to the small size of our cohort,
which did not allow differentiation among all types
of leukemia. In the present study, although the mortal-
ity of RRTs was only 2% (1/50), the day 1100 TRM
was 21.6% (11/51), with a 17.6% mortality (9/51) for
GVHD. Decreasing TRM, especially the lethality of
GVHD, is a worthy goal that merits further study.
In conclusion, our data suggest that sequential
cytoreductive chemotherapy and MA conditioning in
allo-HSCT for adult refractory leukemia is well toler-
ated. Although this approach cannot overcome the
obstacle of cytogenetic status, it appears to improve
OS and DFS. The sequential strategy of cytoreductive
chemotherapy followed immediately by intensified
MA conditioning for allo-HSCT and rapid tapering
of prophylactic immunosuppresants for GVHD
during the early stages posttransplantation may
represent a step forward in the treatment of refractory
leukemia.
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